



3-Deazaneplanocin A (hydrochloride)

Catalog No: tcsc0870

Available Sizes
Size: 1mg
Size: 5mg
Size: 10mg
Size: 25mg
Specifications
CAS No: 120964-45-6
Formula: C ₁₂ H ₁₅ CIN ₄ O ₃
Pathway: Epigenetics;Epigenetics
Target: Histone Methyltransferase;Epigenetic Reader Domain
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: DZNep hydrochloride;NSC 617989 hydrochloride;3-Deazaneplanocin hydrochloride
Observed Molecular Weight: 298.73



Product Description

3-Deazaneplanocin A hydrochloride is a potent **histone methyltransferase EZH2** inhibitor.

IC50 & Target: EZH2^[1]

In Vitro: 3-Deazaneplanocin A (DZNep) hydrochloride is a potent histone methyltransferase EZH2 inhibitor. Treatment of OCI-AML3 cells with 3-Deazaneplanocin A (1.0 μ M) results in a significant increase in accumulation of cells in the G_0/G_1 phase (58.5%) with a concomitant decrease in the number of cells in S phase (35.2%) and G_2/M phases (6.3%) of the cell cycle (P[1]. 3-Deazaneplanocin A (DZNep) hydrochloride reduces the expression of EZH2, especially after 72 hours (e.g. 48%, 32% and 36% reduction of EZH2 in PANC-1, MIA-PaCa-2 and LPc006 cells, respectively)^[2]. 3-Deazaneplanocin A (DZNep) hydrochloride shows minimal growth inhibition in PANC-1 cells. More than 50% of these cells are still growing after exposure at the highest concentration (20 μ M). MIA-PaCa-2 and LPc006 cells are much more sensitive, with IC $_0$ values of 1.0±0.3 and 0.10±0.03 μ M, respectively^[2]. 3-Deazaneplanocin A (DZNep) hydrochloride causes dose-dependent inhibition of cell proliferation of NSCLC cell lines, and the IC $_0$ values range from 0.08 to 0.24 μ M[3].

In Vivo: The survival of NOD/SCID mice with acute myeloid leukemia (AML) due to HL-60 cells is significantly higher, if treated with 3-Deazaneplanocin A (DZNep) and Panobinostat (PS) compare to treatment with PS, 3-Deazaneplanocin A, or vehicle alone (P[1]. There is a progressive increase in weight of rats treated with physiological saline in a time-dependent manner (the mean growth rate=3.19% per day). Administration of 20 mg/kg 3-Deazaneplanocin A (DZNep) not only markedly reduces the relative weight of the rats compare to the initial weight (-2.0%, -4.9% and -1.2%) in the first three days post-treatment, but also suppresses the weight growth rate to 2.6% per day from the fourth day onwards post-dose^[4].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!